


SUPPLEMENTARY DATA

**Conflict-Related Breakdowns in Routine Medical Care -
Longitudinal Outcomes for Civilians with Pre-Existing
Cognitive Impairment**

Zorian Radomyslsky, Sara Kivity, Yaniv Alon, Mor Saban

SUPPLEMENTARY DATA



Supplementary Figure 1. Individual Selection and Exclusion Flow Chart from Baseline to Second Follow-Up. The flow chart delineates the process of selecting and excluding individuals for a comparative study between Study and Control groups, assessed at three key time points: the Baseline (prior to October 7, 2023), the First Follow-up (on December 31, 2023), and the Second Follow-up (on February 27, 2024). Each group assessed on the two subsequent dates, with individuals do not present at all time points being excluded. After each exclusion step, the remaining individuals were normalized by age. The final counts and demographic details at the end of this process are presented for both the Study and Control groups.

Supplementary Table 1. GEE Analysis Results Impact of Time and Group Status on Elderly Different Health Conditions.

Condition	Variable	Coefficient	StdErr	z	P> z	CI_low	CI_high
Dementia	Intercept	-36.640	0.008	-4729.535	p<0.001	-36.655	-36.625
	Period (Follow-up 1 vs. Baseline)	-2.567	0.002	-1146.618	p<0.001	-2.571	-2.562
	Period (Follow-up 2 vs. Baseline)	0.849	0.003	288.186	p<0.001	0.843	0.855
	Group (Study vs. Control)	35.324	0.008	4559.701	p<0.001	35.309	35.340
	PeriodGroup (Follow-up 1Study)	2.531	0.002	1130.818	p<0.001	2.527	2.536
	PeriodGroup (Follow-up 2Study)	-0.888	0.003	-301.518	p<0.001	-0.894	-0.883
Depression	Intercept	-2.317	0.007	-340.901	p<0.001	-2.330	-2.304
	Period (Follow-up 1 vs. Baseline)	-0.403	0.005	-74.936	p<0.001	-0.413	-0.392
	Period (Follow-up 2 vs. Baseline)	-0.374	0.005	-70.369	p<0.001	-0.385	-0.364
	Group (Study vs. Control)	1.378	0.016	88.170	p<0.001	1.348	1.409
	PeriodGroup (Follow-up 1Study)	-0.078	0.013	-6.130	p<0.001	-0.103	-0.053
	PeriodGroup (Follow-up 2Study)	-0.147	0.013	-11.062	p<0.001	-0.173	-0.121
Blood pressure	Intercept	0.587	0.004	144.758	p<0.001	0.579	0.595
	Period (Follow-up 1 vs. Baseline)	-0.105	0.002	-61.729	p<0.001	-0.108	-0.101

SUPPLEMENTARY DATA

	Period (Follow-up 2 vs. Baseline)	-0.023	0.001	-27.764	p<0.001	-0.024	-0.021
	Group (Study vs. Control)	0.632	0.016	40.481	p<0.001	0.601	0.663
	PeriodGroup (Follow-up 1Study)	0.057	0.006	10.288	p<0.001	0.046	0.068
	PeriodGroup (Follow-up 2Study)	-0.040	0.006	-6.250	p<0.001	-0.053	-0.028
Chronic obstructive pulmonary disease (COPD)	Intercept	-2.461	0.007	-341.001	p<0.001	-2.476	-2.447
	Period (Follow-up 1 vs. Baseline)	-0.091	0.003	-32.857	p<0.001	-0.097	-0.086
	Period (Follow-up 2 vs. Baseline)	-0.037	0.002	-16.662	p<0.001	-0.041	-0.032
	Group (Study vs. Control)	0.243	0.022	10.811	p<0.001	0.199	0.287
	PeriodGroup (Follow-up 1Study)	0.075	0.007	10.932	p<0.001	0.061	0.088
	PeriodGroup (Follow-up 2Study)	0.017	0.009	1.986	p<0.05	0.000	0.034
Diabetes mellitus (DM)	Intercept	-0.840	0.004	-198.459	p<0.001	-0.848	-0.832
	Period (Follow-up 1 vs. Baseline)	-0.065	0.002	-39.159	p<0.001	-0.068	-0.061
	Period (Follow-up 2 vs. Baseline)	0.044	0.002	23.794	p<0.001	0.040	0.047
	Group (Study vs. Control)	0.340	0.014	24.776	p<0.001	0.313	0.367
	PeriodGroup (Follow-up 1Study)	0.047	0.004	10.562	p<0.001	0.039	0.056
	PeriodGroup (Follow-up 2Study)	0.000	0.007	-0.023	0.98	-0.014	0.014
Immune suppression	Intercept	-1.591	0.005	-307.050	p<0.001	-1.601	-1.580
	Period (Follow-up 1 vs. Baseline)	-0.133	0.002	-56.269	p<0.001	-0.138	-0.129
	Period (Follow-up 2 vs. Baseline)	-1.105	0.007	-164.481	p<0.001	-1.118	-1.092
	Group (Study vs. Control)	0.157	0.017	9.281	p<0.001	0.123	0.190
	PeriodGroup (Follow-up 1Study)	0.121	0.006	20.136	p<0.001	0.109	0.133
	PeriodGroup (Follow-up 2Study)	0.181	0.019	9.538	p<0.001	0.144	0.218
Obesity	Intercept	-0.960	0.004	-221.166	p<0.001	-0.969	-0.952
	Period (Follow-up 1 vs. Baseline)	0.023	0.001	16.044	p<0.001	0.021	0.026
	Period (Follow-up 2 vs. Baseline)	0.871	0.003	250.168	p<0.001	0.864	0.877
	Group (Study vs. Control)	0.118	0.014	8.159	p<0.001	0.090	0.146
	PeriodGroup (Follow-up 1Study)	-0.035	0.004	-7.981	p<0.001	-0.044	-0.027
	PeriodGroup (Follow-up 2Study)	0.140	0.013	10.879	p<0.001	0.115	0.166
Hip Fracture	Intercept	-2.580	0.008	-339.887	p<0.001	-2.595	-2.565
	Period (Follow-up 1 vs. Baseline)	-1.447	0.014	-101.145	p<0.001	-1.475	-1.419
	Period (Follow-up 2 vs. Baseline)	-1.561	0.016	-95.842	p<0.001	-1.593	-1.529
	Group (Study vs. Control)	0.419	0.022	18.941	p<0.001	0.376	0.463
	PeriodGroup (Follow-up 1Study)	-0.100	0.043	-2.322	p<0.05	-0.184	-0.016
	PeriodGroup (Follow-up 2Study)	-0.053	0.046	-1.164	0.24	-0.143	0.036
Antipsychotic usage	Intercept	-3.211	0.010	-319.016	p<0.001	-3.230	-3.191
	Period (Follow-up 1 vs. Baseline)	-0.630	0.011	-57.931	p<0.001	-0.651	-0.608
	Period (Follow-up 2 vs. Baseline)	-0.728	0.012	-60.202	p<0.001	-0.752	-0.705
	Group (Study vs. Control)	2.036	0.018	113.249	p<0.001	2.001	2.072
	PeriodGroup (Follow-up 1Study)	0.167	0.017	9.969	p<0.001	0.134	0.200
	PeriodGroup (Follow-up 2Study)	0.159	0.019	8.355	p<0.001	0.122	0.196
Antipsychotic prescriptions	Intercept	-3.376	0.011	-310.726	p<0.001	-3.397	-3.354
	Period (Follow-up 1 vs. Baseline)	-0.597	0.012	-51.070	p<0.001	-0.620	-0.574
	Period (Follow-up 2 vs. Baseline)	-0.775	0.014	-56.788	p<0.001	-0.802	-0.748

SUPPLEMENTARY DATA

	Group (Study vs. Control)	1.994	0.019	104.018	p<0.001	1.957	2.032
	PeriodGroup (Follow-up 1Study)	0.065	0.019	3.414	p<0.001	0.028	0.103
	PeriodGroup (Follow-up 2Study)	0.063	0.022	2.807	p<0.01	0.019	0.107
Antidepressant Usage	Intercept	-1.278	0.005	-271.636	p<0.001	-1.287	-1.269
	Period (Follow-up 1 vs. Baseline)	-0.514	0.004	-126.569	p<0.001	-0.522	-0.506
	Period (Follow-up 2 vs. Baseline)	-0.640	0.005	-138.915	p<0.001	-0.649	-0.631
	Group (Study vs. Control)	1.292	0.014	95.669	p<0.001	1.265	1.318
	PeriodGroup (Follow-up 1Study)	-0.110	0.012	-9.475	p<0.001	-0.133	-0.087
	PeriodGroup (Follow-up 2Study)	-0.157	0.013	-11.996	p<0.001	-0.183	-0.131
Antidepressant prescriptions	Intercept	-1.260	0.005	-269.135	p<0.001	-1.269	-1.251
	Period (Follow-up 1 vs. Baseline)	-0.517	0.004	-124.718	p<0.001	-0.525	-0.509
	Period (Follow-up 2 vs. Baseline)	-0.699	0.005	-144.654	p<0.001	-0.709	-0.690
	Group (Study vs. Control)	1.194	0.014	88.447	p<0.001	1.168	1.220
	PeriodGroup (Follow-up 1Study)	-0.129	0.012	-10.740	p<0.001	-0.153	-0.106
	PeriodGroup (Follow-up 2Study)	-0.203	0.014	-14.552	p<0.001	-0.231	-0.176
Eligible for Home Treatments	Intercept	-4.327	0.017	-252.720	p<0.001	-4.360	-4.293
	Period (Follow-up 1 vs. Baseline)	-0.385	0.012	-33.271	p<0.001	-0.407	-0.362
	Period (Follow-up 2 vs. Baseline)	-0.361	0.016	-22.884	p<0.001	-0.391	-0.330
	Group (Study vs. Control)	2.019	0.028	72.306	p<0.001	1.964	2.074
	PeriodGroup (Follow-up 1Study)	0.192	0.018	10.729	p<0.001	0.157	0.227
	PeriodGroup (Follow-up 2Study)	0.151	0.023	6.609	p<0.001	0.106	0.195

Summarized results from a Generalized Estimating Equations (GEE) analysis evaluated the impact of time periods and group status on various health conditions within an elderly population. The analysis includes coefficients, standard errors, z-scores, p-values, and confidence intervals for each variable in the model. Assessed conditions encompass Dementia, Depression, Chronic Obstructive Pulmonary Disease (COPD), Diabetes Mellitus (DM), Immune Suppression, Obesity, Hip Fracture, Eligibility for Home Treatments, and usage/prescriptions of Antidepressant and Antipsychotic medications. Variables indicate comparisons between time periods and differences between the control and study groups as follows: Intercept: The average outcome at the start of the study for the control group. Period (Follow-up 1 vs. Baseline): The change in the outcome from baseline to the first follow-up. Period (Follow-up 2 vs. Baseline): The change in the outcome from baseline to the second follow-up. Group (Study vs. Control): The difference in outcome between the study group and control group at baseline. PeriodGroup (Follow-up 1Study): The difference in the first follow-up changes between the study and control groups. PeriodGroup (Follow-up 2Study): The difference in the second follow-up changes between the study and control groups.

Supplementary Table 2. Associations Between Depression, Antidepressant Use, and Immune Suppression: Mixed Linear Model Analysis.

Model:	MixedLM	Dependent Variable:	Immune suppression			
No. Observations:	876656	Method:	REML			
No. Groups:	2	Scale:	0.1120			
Min. group size:	77373	Log-Likelihood:	-284209.2698			
Max. group size:	799283	Converged:	Yes			
Mean group size:	438328.0					
index	Coef.	Std.Err.	z	P> z	[0.025	0.975]
Intercept	0.175	0.237	0.742	0.458	-0.288	0.639
Time	-0.050	0.237	-0.211	0.833	-0.514	0.414
Depression	0.048	0.002	24.244	0.000	0.044	0.052
Antidepressant adherence	0.051	0.001	47.799	0.000	0.049	0.053
Depression:Antidepressant adherence	-0.045	0.003	-16.490	0.000	-0.050	-0.039
Group Var	0.112					

SUPPLEMENTARY DATA

Group x Time Cov	0.000					
Time Var	0.112					

Results of a mixed linear model regression assessing the effects of depression diagnosis and antidepressant use on immune suppression, based on 876,656 observations.